A share price of MBX Biosciences Inc [MBX] is currently trading at $40.53, down -0.93%. An important factor to consider is whether the stock is rising or falling in short-term value. The MBX shares have gain 28.02% over the last week, with a monthly amount glided 46.05%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
MBX Biosciences Inc [NASDAQ: MBX] stock has seen the most recent analyst activity on December 04, 2025, when Goldman initiated its Sell rating and assigned the stock a price target of $18. On October 15, 2025, Truist initiated with a Buy rating and assigned a price target of $50 on the stock. Mizuho initiated its recommendation with an Outperform and recommended $38 as its price target on August 05, 2025. Oppenheimer started tracking with an Outperform rating for this stock on July 16, 2025, and assigned it a price target of $38. In a note dated April 10, 2025, Citizens JMP initiated an Mkt Outperform rating and provided a target price of $38 on this stock.
MBX Biosciences Inc experienced fluctuations in its stock price throughout the past year between $4.81 and $44.89. Currently, Wall Street analysts expect the stock to reach $50.8 within the next 12 months. MBX Biosciences Inc [NASDAQ: MBX] shares were valued at $40.53 at the most recent close of the market. An investor can expect a potential return of 25.34% based on the average MBX price forecast.
Analyzing the MBX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.29 and Total Capital is -0.23. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
To put it in perspective, the Current Ratio for MBX Biosciences Inc [NASDAQ:MBX] is 32.95. On the other hand, the Quick Ratio is 32.95, and the Cash Ratio is 18.5.
Transactions by insiders
Recent insider trading involved CORNELIUS JAMES M, Former Director, that happened on Jan 12 ’26 when 30864.0 shares were purchased. President & CEO, Hawryluk P. Kent completed a deal on Oct 20 ’25 to buy 20000.0 shares. Meanwhile, Director Hoerter Steven L. bought 20000.0 shares on Oct 17 ’25.
